It does the job we expected, shipped quickly, and was the best in price compared to competitors.
SML2282
エベロリムス
≥95% (HPLC), powder, P-glycoprotein substrate
Everolimus
1のうち1の評価者がサンプル商品を受け取ったか、プロモーションに参加しました
別名:
Everolimus, 40-O-(2-Hydroxyethyl)rapamycin, 42-O-(2-Hydroxyethyl)-rapamycin, RAD 001, RAD001, SDZ-RAD, 42-O-(2-Hydroxyethyl)rapamycin
ログインで組織・契約価格をご覧ください。
この商品について
実験式（ヒル表記法）:
C53H83NO14
CAS番号:
分子量:
958.22
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
スキップする
製品名
エベロリムス, ≥95% (HPLC)
InChI key
HKVAMNSJSFKALM-GKUWKFKPSA-N
SMILES string
O=C(C([C@@]1(O)[C@H](C)CC[C@](C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C2=O)([H])O1)=O)N3[C@H](C(O[C@@]([C@@H](C[C@@]4([H])C[C@@H](OC)[C@H](OCCO)CC4)C)([H])CC([C@H](C)/C=C(C)/[C@@H](O)[C@H]2OC)=O)=O)CCCC3
InChI
1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
shipped in
wet ice
storage temp.
−20°C
Quality Level
Gene Information
human ... FKBP1A(2280)
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
1 of 4
当該品目 | Y0002048 | 94687 | Y0002063 |
|---|---|---|---|
| assay ≥95% (HPLC) | assay - | assay ≥75.0% (qNMR) | assay - |
| form powder | form - | form - | form - |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| solubility DMSO: 2 mg/mL, clear | solubility - | solubility - | solubility - |
| shipped in wet ice | shipped in - | shipped in - | shipped in - |
| color white to beige | color - | color - | color - |
Application
Everolimus has been used as an mechanistic target of rapamycin complex 1 (mTORC1) inhibitor to study its effect on MCF7 and MDA-MB-231 cell lines.[1]
Biochem/physiol Actions
Everolimus, a substrate for P-glycoprotein (P-gp) can be used to treat advanced neuroendocrine tumors (NETs).[2]
Everolimus, the 40-O-(2-hydroxyethyl) derivative of rapamycin (sirolimus), is a potent and selective inhibitor of mechanistic target of rapamycin (mTOR). Everolimus is selective for the mTORC1 protein complex. Everolimus exhibit potent immunosuppressive and anticancer activities.
signalword
Warning
hcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Repr. 2 - STOT RE 2
target_organs
Kidney,Testes
保管分類
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Chemical modification of rapamycin: the discovery of SDZ RAD.
R Sedrani et al.
Transplantation proceedings, 30(5), 2192-2194 (1998-09-02)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lee L, et al.
Expert Opinion on Pharmacotherapy, 19(8), 909-928 (2018)
Heidi A Lane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(5), 1612-1622 (2009-02-19)
Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular endothelial growth factor receptor (VEGFR) inhibitor vatalanib (PTK/ZK). Antiproliferative activity against various tumor histotypes and downstream effects on the mTOR pathway
Gerke Ariaans et al.
BMC cancer, 17(1), 232-232 (2017-03-31)
Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia, as well as enhancing anti-cancer efficacy. We investigated the glucose-dependent
O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes
Barkovskaya A, et al.
Scientific Reports, 9(1), 5670-5670 (2019)
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）